BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Symphogen A/S Names Martin Olin Chief Financial Officer and Receives 2nd Tranche From €100 Million 2011 Financing


4/2/2012 6:57:28 AM

COPENHAGEN, Denmark--(BUSINESS WIRE)-- Symphogen announced today the appointment of Martin Olin to the position of Chief Financial Officer. Symphogen also said it received the second of three tranches of capital specified in its €100 million 2011 financing.

Martin Olin joins Symphogen from Scandinavia Life Science Invest (SLS Invest), where since 2000 he has been Senior Investment Director and a Senior Partner of the evergreen investment company focused on supporting small and medium-sized life science companies. Prior to his position with SLS Invest, Olin was with Novo Nordisk, most recently as the Finance Director EMEA managing finance, IT, and customer service for the region. Olin has more than a decade of executive experience with life science companies and has been involved in numerous private equity transactions, trade sales and commercial partnerships. He currently serves as a director on the board of several life science companies in the US and in Europe. Olin has an Executive MBA from the Scandinavian International Management Institute, and an HA and MSc. from the Copenhagen Business School.

Symphogen also reported that the company had met a key clinical milestone specified by the investors in its €100 million financing announced in January 2011. Novo A/S led the round and was joined by Essex Woodlands together contributing 70% of the investment. Under the agreement, Symphogen was required to meet key clinical milestones demonstrating the company’s ability to accelerate advancement of its lead clinical oncology product Sym004. The first of these milestones has now been successfully met and the second tranche of capital has been received by Symphogen.

Kirsten Drejer, Ph.D., Symphogen’s Chief Executive Officer, commented, “Martin Olin brings to Symphogen more than a decade of international life science experience in finance, strategic operations and the public markets. No stranger to Symphogen, he sat on our Board from 2001 – 2008 and provided key leadership while we grew the company from a vision to a sustainable business entity. We all look forward to his contributions as we enter a new growth phase and advance our clinical candidates toward the market. In particular, the data that has been presented on our lead candidate, Sym004, has increased awareness of our breakthrough antibody mixture approach. Having met the criteria set by our investors to secure the second tranche of funding, we believe we are strongly positioned to grow organically and in collaboration with our partners.”

Dr. Drejer said that Thomas Feldthus, a co-founder of the company and formerly, CFO, had left the company to pursue other interests.

“Thomas was with us from the beginning, and his presence will be missed,” added Dr. Drejer. “Thomas’ vision and his leadership was felt throughout the company, and we wish him the best as he moves forward to new challenges and opportunities.”

About Symphogen

Symphogen is developing superior antibody therapeutics (monoclonal, monoclonal mixtures and polyclonal) to help people with serious diseases and significant unmet medical needs. With its proprietary, unique Symplex™ discovery, SymSelect™ lead selection and Sympress™ manufacturing platforms, the company captures the diversity and specificity of the natural immune response in rationally designed recombinant antibody compositions. Symphogen is maturing a diversified pipeline of internal and partnered products across multiple indications including cancer, autoimmune and infectious disease. Symphogen is a private biopharmaceutical company headquartered in Copenhagen, Denmark, with a US subsidiary in Princeton, New Jersey. For more information, please visit www.symphogen.com.

Contact:

Symphogen A/S

Dr. Kirsten Drejer, +45 22 10 99 59

+45 45 26 50 50

Chief Executive Officer

kd@symphogen.com

or

Ms. Heidi K. Roennest, +45 61 18 74 94

Executive Office Manager & PA to CEO Kirsten Drejer

hkr@symphogen.com



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES